Quebec Drug Cover Program Slammed

18 August 1996

In Canada, Quebec's new prescription drug insurance program, which took effect on August 1 after enabling legislation was rushed through, has been attacked for placing too heavy a burden on senior citizens and those on welfare. Under the program, these groups are now required to pay 25% of the cost of their medicines.

The province's ombudsman, Daniel Jacoby, has called for changes to be made to the program during the August 1-January 1, 1997, transition period, and says that the mentally-ill and people under curatorship should not have to pay for their medication. Mr Jacoby told the provincial health department that he could "only deplore" the program, and warned that he would be keeping a close eye on it, in order to "prevent foulups, undue delays and unfair treatment on account of poor program management."

The program has also been denounced by Stephen Soumerai, director of the drug policy research group at Harvard University. He told the Montreal Gazette that there was "no question" that senior citizens and welfare recipients would take fewer drugs as a result of the program, and thus endanger their health. "People will try to take less of their medications, which can be unsafe," he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight